stella
beta
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases — Stella
Recruiting
Back to Idiopathic Inflammatory Myopathies(IIM) trials
Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.
Trial locations
(1 site)
China
Shanghai Mengchao Cancer Hospital, Shanghai, Shanghai Municipality
View full record on ClinicalTrials.gov